Ex Vivo Cultures of diseased and normal human tissue for translational research and defining personalised healthcare; Collaboration project with Merck for the use of predictive human organocultures

There is currently a need for preclinical models that better predict the clinical effectiveness and safety of drug therapies, this is demonstrated by the high attrition rate seen across the pharmaceutical industry particularly in late stage clinical development.

The Technology Strategy Board SMART award is providing funding to Biopta in collaboration with Merck to explore the development of human ex vivo organoculture assays in the Chronic Obstructive Pulmonary Disease (COPD) and Rheumatoid Arthritis (RA) therapeutic areas.

The aim is to develop a platform of tests in human ex-vivo translational models to better predict clinical efficacy.  To define a standard procedure for testing potential new drug compounds in diseased tissue and assess the clinical prediction of the outcomes through comparisons to existing standard of care drugs.  In the future it will provide information about possible personalised medicine opportunities by recognising patient stratification and identifying predictive gene signatures. 

For information on The Technology Strategy Board and Merck please visit:



Live chat by BoldChat